Evidence map›Paper›PMID 40654867›Full record

ArticlebioRxiv : the preprint server for biology2025

EpiMII: Integrating Structure and Graph Neural Networks for MHC-II Epitope and Neoantigen Design.

Jiayi Yuan, Xiaowei Xu, Ze-Yu Sun, Tianjian Liang, Jingxuan Ge, Ruofan Jin, Xiang-Qun Xie, Yan Chen, Tingjun Hou, Zhiwei Feng

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiayi YuanDepartment of Pharmaceutical Sciences, Computational Chemical Genomics Screening Center, and Pharmacometrics & System Pharmacology PharmacoAnalytics, School of Pharmacy; National Center of Excellence for Computational Drug Abuse Research, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States.
Xiaowei XuCollege of Pharmacology Sciences, Zhejiang University of Technology, 999 Changhong East Street and 1 Gongda Road, Deqing County, Huzhou City, Zhejiang Province, China.
Ze-Yu SunDepartment of Pharmaceutical Sciences, Computational Chemical Genomics Screening Center, and Pharmacometrics & System Pharmacology PharmacoAnalytics, School of Pharmacy; National Center of Excellence for Computational Drug Abuse Research, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States.
Tianjian LiangDepartment of Pharmaceutical Sciences, Computational Chemical Genomics Screening Center, and Pharmacometrics & System Pharmacology PharmacoAnalytics, School of Pharmacy; National Center of Excellence for Computational Drug Abuse Research, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States.
Jingxuan GeCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China.
Ruofan JinCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China.
Xiang-Qun XieDepartment of Pharmaceutical Sciences, Computational Chemical Genomics Screening Center, and Pharmacometrics & System Pharmacology PharmacoAnalytics, School of Pharmacy; National Center of Excellence for Computational Drug Abuse Research, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States.ORCID 0000-0002-6881-6175
Yan ChenCollege of Pharmacology Sciences, Zhejiang University of Technology, 999 Changhong East Street and 1 Gongda Road, Deqing County, Huzhou City, Zhejiang Province, China.ORCID 0000-0003-0777-9427
Tingjun HouCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, Zhejiang, China.ORCID 0000-0001-7227-2580
Zhiwei FengDepartment of Pharmaceutical Sciences, Computational Chemical Genomics Screening Center, and Pharmacometrics & System Pharmacology PharmacoAnalytics, School of Pharmacy; National Center of Excellence for Computational Drug Abuse Research, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States.ORCID 0000-0001-6533-8932

Funding

NIDA Center of Excellence OF Computational Drug Abuse Research (CDAR)P30DA035778 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BAHAR, IVET, XIE, XIANG-QUN · 2014 to 2018
$5.4M
Cannabinoid CB2 Receptor Structure and Allosteric ModulatorsR01DA052329 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI XIE, XIANG-QUN, ZHANG, CHENG · 2021 to 2024
$2.5M
NIDA NIH HHS P30 DA035778NIDA NIH HHS R01 DA052329
6 · The paper itself

Abstract

MHC-II neoantigens play a critical role in immunotherapy, either as direct effectors or through their influence on CD8

Indexed as

CD4+ T cellsdesignmachine learningMHC-II epitopesneoantigensvaccine

Identifiers

PMID40654867
PMCPMC12248154

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.